Evaluation of the analgesic effect of Pregabalin for joint pain after Chikungunya.

Phase 1

• Conditions: Joint pain; Chikungunya; A92.0; M25.5

• Registration Number: RBR-6mkndk
• Lead Sponsor: Rodrigo Souza Rodrigues

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-11-11
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

35 participants will be included aged 18 to 100 years old; Both sexes; With chronic illness (more than 3 months); Individuals with arthralgia after chikungunya, previously diagnosed with sorology positive for CHIK; Individuals with pain upper than 4

Exclusion Criteria

Non-inclusion criteria patient with sorologies for CHIK with negative IGG and positive IGM; FR (rheumatoid factor) and FAN (antinuclear factor) positive in high values; Cognitive dysfunction (unable to understand the explanations); Psychiatric illness; Drug user; Pregnancy

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The present study aims to assess the decrease in pain intensity with the use of pregabalin associated with hydroxychloroquine, compared with hydroxychloroquine alone for patients with chikungunya.<br>Pain assessment will be on the verbal numeric scale from 0 to 10, before the start of the medication and after 2weeks, 1m, 2m and 3m.

Secondary Outcome Measures

Name	Time	Method
An improvement in quality of life is expected due to improved pain scores both in the control group and in the intervention group, but with greater intensity in the intervention group, which will be assessed through the WHOQOL-100 questionnaire which will be applied at the beginning and at the end of the study<br>;Assess the occurrence of side effects of the studied drugs and supplemental analgesics